Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuadrise Regulatory News (QED)

Share Price Information for Quadrise (QED)

Share Price is delayed by 15 minutes
Get Live Data
1.995    -0.215 (-9.73%)
Bid:
1.905
Ask:
2.19
Spread: 0.285 (14.961%)
Market Cap: £40.02m
QED Live PriceLast checked at - London Stock Exchange

Intraday Quadrise Share Chart

OCP Commercial Framework Agreement

28 May 2024 07:00

RNS Number : 9596P
Quadrise PLC
28 May 2024
 

28 May 2024

 

Quadrise plc

("Quadrise" or the "Company")

 

OCP Commercial Framework Agreement

 

Quadrise Plc (AIM: QED), the supplier of innovative energy solutions for a cleaner planet, is pleased to announce the signature of a Commercial Framework Agreement (the "Agreement") with its client in Morocco, OCP S.A. ("OCP"), an international manufacturing and mining group.

Under the Agreement, Quadrise and OCP will commence commercial discussions with third parties for MSAR® supply to OCP. Simultaneously, the parties have agreed to work together on a paid-for commercial trial at OCP's Jorf Lasfar site ('the Site').

The three components of the Agreement are as follows:

1) Commencing from the date of the Agreement, Quadrise will approach suppliers (refineries, terminal operators and/or traders) who have the capacity to produce MSAR® to meet OCP's demand. To facilitate discussions, OCP have signed a Letter of Intent stating their intention to enter into a Commercial Supply Agreement with a supplier, who would supply MSAR® to OCP under licence from Quadrise.

2) Quadrise will provide an update to the technical, economic and feasibility study that was previously issued in June 2022, to convert the Site for the consumption of MSAR®.

3) Quadrise will supply and install equipment (including a 5 tonne per hour MSAR® Manufacturing Unit) to emulsify locally available heavy fuel oil using MSAR® technology. A 30-day MSAR® combustion trial will then be carried out on a kiln at the Site. Execution of a Commercial Supply Agreement is conditional upon successful results of this trial.

Commenting on this agreement Jason Miles, CEO Quadrise, said:

"This Agreement marks a hugely significant step for Quadrise. We are delighted to be progressing towards the commercialisation of our technology with OCP, who are world leader in their sector. This Agreement provides a clear pathway to long term commercial revenues and an opportunity to create a supply point for our fuels in the Mediterranean, a strategic location for marine bunkering.

We look forward to progressing commercial supply discussions with prospective suppliers and to working with the OCP team to complete the commercial trial. Based on the success of the previous trial, we have every confidence in its successful conclusion."

Summary of Agreement

Under the Agreement, Quadrise and OCP will immediately start work to identify, and then enter commercial discussions with commercial supply partners.

In parallel, Quadrise will progress the work already carried out under the June 2022 Material Transfer & Cooperation Agreement with OCP, under which MSAR® and bioMSAR trials were successfully completed in November 2023 and a feasibility study for commercial use of MSAR® at OCP's Jorf Lasfar site was prepared. Quadrise will update the feasibility study to include details of the equipment and methodology to convert the Jorf Lasfar site to the use of MSAR® fuel.

A 30-day MSAR® test at a kiln at the Jorf Lasfar site (formerly referred to as 'Site-A') will be carried out to assess the long-term operational performance of MSAR® fuel. The MSAR® fuel will be manufactured on-site using heavy fuel oil following the installation of a 5 tonne per hour MSAR® Manufacturing Unit and associated equipment.

The Agreement is for a term of one year, unless mutually extended, and may be terminated by mutual agreement or by one party if a breach of the Agreement has occurred. 

For additional information, please contact:

 

Quadrise Plc

+44 (0)20 7031 7321

Andy Morrison, Chairman

Jason Miles, Chief Executive Officer

Nominated Adviser

Cavendish Capital Markets Limited

+44 (0)20 7220 0500

Ben Jeynes

Katy Birkin

George Lawson

Joint Brokers

Shore Capital Stockbrokers Limited

 

 

+44 (0)20 7408 4090

Toby Gibbs, Rachel Goldstein (Corporate Advisory)

Fiona Conroy (Corporate Broking)

 

 

 

VSA Capital Limited

Andrew Raca (Corporate Finance)

Andrew Monk (Corporate Broking)

+44 (0)20 3005 5000

Public & Investor Relations

 

 

Vigo Consulting

Patrick D'Ancona

Finlay ThomsonPeter Jacob

+44 (0)20 7390 0230

 

About Quadrise

 

Quadrise is the supplier of MSAR® and bioMSAR™ emulsion technology, fuels and biofuels, providing innovative solutions to reduce energy costs and greenhouse gas emissions today for clients in the global power generation, shipping, industrial and refining industries.

Learn more at: www.quadrise.com

 

Follow us on social media:

LinkedIn: @Quadrise Plc

X (formerly Twitter): @QuadrisePlc

 

About OCP

 

OCP is a leader in plant nutrition and the world's first producer of phosphate-based fertilizers. OCP provides a wide range of customized fertilizer products to enhance soil, increase agricultural yields, and help feed the planet in a sustainable and affordable way.

Learn more at: www.ocpgroup.ma

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR") and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBIGDUDSDDGSR
Date   Source Headline
15th Apr 20267:00 amRNSDirectorate change
23rd Mar 20267:00 amRNSInterim Results & Notice of Investor Presentation
19th Mar 20267:00 amRNSAppointment of Non-Executive Director
3rd Feb 20267:00 amRNS-RPublication of 2025 Sustainability Report
12th Jan 20267:00 amRNSExtension of Exclusive Agreement with Nouryon
9th Jan 20267:00 amRNSDirector/PDMR Shareholding and Directorate Change
4th Dec 202512:17 pmRNSDirector/PDMR Shareholding
28th Nov 20252:55 pmRNSResult of AGM
28th Nov 20257:00 amRNSAGM Statement
7th Nov 20253:01 pmRNSDirector/PDMR Shareholding
6th Nov 20251:46 pmRNSDirector/PDMR Shareholding
28th Oct 20255:23 pmRNSPosting of Annual Report and Notice of AGM
27th Oct 20257:00 amRNSIssue of Options and Director Dealing
13th Oct 20257:00 amRNSIssue of Share Options and Director/PDMR Dealing
29th Sep 20257:00 amRNSFinal Results and Notice of AGM
26th Sep 20257:00 amRNSValkor update
17th Sep 20257:00 amRNSSuccessful Sparkle Power Programme Testing
15th Sep 20257:00 amRNSCEO Appointment
18th Aug 20257:00 amRNSBusiness Update
25th Jul 20257:00 amRNSDirector / PDMR Shareholding
14th Jul 20258:00 amRNSDirector/PDMR Shareholding
4th Jul 202511:50 amRNSExercise of Options and Total Voting Rights
17th Jun 20257:00 amRNSJoint Development Agreement with Alder Energy LLC
10th Jun 20257:00 amRNSBusiness Update
23rd May 20257:00 amRNSExercise of Warrants
1st May 20257:01 amRNSTotal Voting Rights
1st May 20257:00 amRNSManagement Update
3rd Apr 20257:00 amRNSExercise of Share Options
1st Apr 20257:00 amRNSMAC2 Services Agreement
26th Mar 202512:46 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSLicella Joint Development Agreement
24th Mar 20257:00 amRNSInterim Results and Investor Presentation
13th Mar 20257:00 amRNS-RAppointment of Head of Marine
31st Jan 20257:00 amRNSResult of Retail Offer
30th Jan 20252:36 pmRNSIncrease of Retail Offer
28th Jan 20257:00 amRNSAppointment of Director
24th Jan 202510:04 amRNSRetail Offer - Notice of IMC Presentation
24th Jan 20257:05 amRNSRetail Offer
24th Jan 20257:00 amRNSResult of Placing and Subscription
23rd Jan 20254:51 pmRNSProposed Placing, Subscription and Retail Offer
15th Jan 20257:00 amRNSValkor License Revenues
16th Dec 20247:00 amRNSMaterial Transfer Agreement with Sparkle Power SA
5th Dec 20247:00 amRNS-RbioMSAR™ Development Update
26th Nov 20247:00 amRNSProject Agreement with MSC and Cargill
25th Nov 20247:00 amRNSCollaboration Agreement with Auramarine
22nd Nov 20244:57 pmRNSResult of AGM
22nd Nov 20247:00 amRNSAGM Statement
25th Oct 20244:05 pmRNSPosting of Annual Report & Notice of AGM
30th Sep 20247:00 amRNSFinal Results and Notice of AGM
2nd Aug 20247:00 amRNSIssue of Share Options and Director/PDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.